Patent US4418069A successfully refreshed from Google Patents.
US4418069A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Benzisoselenazolones and process for the treatment of rheumatic and arthritic diseases using them
Assignee: A Natterman und Cie GmbH
•
Filing: 1981-07-09
•
Granted: 1983-11-29
•
Expires: 2001-07-09
Abstract
Abstract The present invention is related to new benzisoselenazolones having the general formula I ##STR1## new products having the general formula II ##STR2## used as intermediary products in the production of the compounds of formula I and a method for the treatment of rheumatic diseases using a compound of formula I as active agent.
Inventors
- 👤 Andre Welter
- 👤 Leon Christiaens
- 👤 Ferdinand Wirtz-Peitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:49
CPC Classifications
C; C07; C07D; C07D421/00; C07D421/02; C07D421/04; A; A61; A61P; A61P29/00; C07C; C07C391/00; C07C391/02; C07D293/00; C07D293/10; C07D293/12; C07D317/00; C07D317/08; C07D317/44; C07D317/46; C07D317/48; C07D317/62; C07D317/66; C07D517/00; C07D517/02; C07D517/04
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
204 words
A benzisoselenazolone having the general formula I ##STR53## wherein R 1 and R 2 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl, C 1 to 4 -alkoxy, hydroxy, trifluoromethyl, nitro, or R 1 and R 2 together represent the methylenedioxy group --O--CH 2 --O--, R 3 and R 4 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl, C 1 to 4 -alkoxy, hydroxy, trifluoromethyl, nitro, di-(C 1 to 4 -alkyl)-amino or, R 3 and R 4 together, represent the methylenedioxy group --O--CH 2 --O-- or R 3 represents hydrogen with R 4 being --CN, --COOR 5 or ##STR54## wherein R 5 is hydrogen, an alkali metal ion or C 1 to 4 -alkyl and R 6 being hydrogen, methyl or ethyl, and n is 0 or an integer from 1 to 4, with the exclusion of the compounds of formula I, wherein n is 0, R 1 , R 2 and R 3 are hydrogen and R 4 is hydrogen or o-methyl or n is 1 and R 1 , R 2 , R 3 and R 4 are hydrogen.
Claim 2
Dependent Claim
204 words
A benzisoselenazolone having the general formula I ##STR53## wherein R 1 and R 2 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl, C 1 to 4 -alkoxy, hydroxy, trifluoromethyl, nitro, or R 1 and R 2 together represent the methylenedioxy group --O--CH 2 --O--, R 3 and R 4 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl, C 1 to 4 -alkoxy, hydroxy, trifluoromethyl, nitro, di-(C 1 to 4 -alkyl)-amino or, R 3 and R 4 together, represent the methylenedioxy group --O--CH 2 --O-- or R 3 represents hydrogen with R 4 being --CN, --COOR 5 or ##STR54## wherein R 5 is hydrogen, an alkali metal ion or C 1 to 4 -alkyl and R 6 being hydrogen, methyl or ethyl, and n is 0 or an integer from 1 to 4, with the exclusion of the compounds of formula I, wherein n is 0, R 1 , R 2 and R 3 are hydrogen and R 4 is hydrogen or o-methyl or n is 1 and R 1 , R 2 , R 3 and R 4 are hydrogen.
Claim 3
Dependent Claim
43 words
A benzisoselenazolone as claimed in claim 1 wherein in formula I n is 0 and either R 1 and R 2 or R 1 and R 3 represent hydrogen with the other substituents being fluorine, chlorine, bromine, hydroxy, methoxy, methyl, trifluoromethyl and/or nitro.
Claim 4
Dependent Claim
65 words
A benzisoselenazolone as claimed in claim 1 wherein in formula I n is 0 or an integer from 1 to 4, R 1 , R 2 and R 3 represent hydrogen and R 4 is --CN, --COOR 5 or ##STR55## R 5 being H, Na.sup.⊕, --CH 3 or --C 2 H 5 and R 6 being H, --CH 3 or --C 2 H 5 .
Claim 5
Dependent Claim
55 words
Process for the treatment of inflammation symptoms of rheumatic and arthritic diseases comprising administering to the being suffering from such disease a compound according to claim 1, 2 or 3 in an amount corresponding to 10 to 1000 mg. per day until the desired degree of alleviation of the symptoms of such disease is achieved.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-28 | 1987-05-30 | 1987-11-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-28 | 1991-05-30 | 1991-11-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-28 | 1995-05-30 | 1995-11-29 | $7700.00 | Window Closed / Lapsed |